Results 1 to 10 of about 416,692 (196)

Safety of the Recombinant Cholera Toxin B Subunit, Killed Whole-Cell (rBS-WC) Oral Cholera Vaccine in Pregnancy [PDF]

PLoS Neglected Tropical Diseases, 2012
Mass vaccinations are a main strategy in the deployment of oral cholera vaccines. Campaigns avoid giving vaccine to pregnant women because of the absence of safety data of the killed whole-cell oral cholera (rBS-WC) vaccine. Balancing this concern is the
Kamala Thriemer, Jacqueline L Deen, Benedikt Ley   +2 more
exaly   +4 more sources

The case for evaluation of double mutant heat-labile toxin as an adjuvant to improve oral cholera vaccine immunogenicity [PDF]

Frontiers in Immunology
Cholera has re-emerged as a major global public health threat. Orally administered attenuated or inactivated vaccines offer protection against enteric pathogens such as Vibrio cholerae, and several World Health Organization-prequalified oral cholera ...
A. Louis Bourgeois, A. Louis Bourgeois, Daniel A. Scott, Shahida Baqar, Shahida Baqar, David R. Tribble, David R. Tribble, Ann-Mari Svennerholm, Richard I. Walker   +8 more
doaj   +2 more sources

Uptake likelihood assessment of oral cholera vaccine capsules: insights from stakeholder consultations in five countries [PDF]

BMC Public Health
Background The global resurgence of cholera, a diarrhoeal disease, has resulted in vaccine demand that exceeds the currently available supply resulting in global calls for next generation cholera vaccines.
Dijana Spasenoska, Anna-Lea Kahn, Malika Bouhenia, Naveena Aloysia D’Cor, Jung-Seok Lee, Se Eun Park, Julia Lynch   +6 more
doaj   +2 more sources

Effectiveness of two doses of Euvichol-plus oral cholera vaccine in response to the 2017/2018 outbreak: a matched case–control study in Lusaka, Zambia [PDF]

BMJ Open, 2022
Introduction Zambia experienced a major cholera outbreak in 2017–2018, with more than 5905 cases reported countrywide, predominantly from the peri-urban slums of Lusaka city.
Victor M Mukonka, Modest Mulenga, C Michelo, Khozya Zyambo, Cephas Sialubanje, Muzala Kapina, Orbrie Chewe, Belem Blamwell Matapo, Albertina Moraes Ngomah, Brittany Gianetti, William Ngosa, Mpanga Kasonde, Kunda Musonda, Nyambe Sinyange, Patricia Bobo, Lucy Mazyanga, Nathan Bakyaita   +16 more
doaj   +2 more sources

Use of Oral Cholera Vaccines in an Outbreak in Vietnam: A Case Control Study [PDF]

PLoS Neglected Tropical Diseases, 2011
BACKGROUND: Killed oral cholera vaccines (OCVs) are available but not used routinely for cholera control except in Vietnam, which produces its own vaccine.
John David Clemens, Anna Lena Lopez, Nguyen Tran Hien   +2 more
exaly   +2 more sources

Development of DuoChol, a Thermostable Inactivated Whole-Cell/B-Subunit Oral Cholera Vaccine in Enteric Capsule [PDF]

Vaccines
Background/Objectives: Cholera remains an important global health problem. Inactivated oral cholera vaccines (OCVs) are essential in the WHO/GTFCC (World Health Organization/Global Task Force on Cholera Control) strategy to end cholera by 2030; however ...
Manuela Terrinoni, Michael R. Lebens, Stefan L. Nordqvist, Frida Nilsson, Madeleine Löfstrand, Julia Lynch, Jan Holmgren   +6 more
doaj   +2 more sources

Evaluation of oral cholera vaccine (Euvichol-Plus) effectiveness against Vibrio cholerae in Bangladesh: an interim analysis [PDF]

BMJ Global Health
Introduction Millions of Euvichol-Plus doses have been deployed from the global oral cholera vaccine stockpile in over 20 cholera-affected countries. However, information on Euvichol-Plus’s effectiveness is limited.
Amanda Tiffany, Ashraful Islam Khan, Firdausi Qadri, John D Clemens, Faisal Ahmmed, Farhana Khanam, Tahmina Shirin, Fahima Chowdhury, Md. Taufiqul Islam, Md Nazmul Islam, Md Nazmul Hasan Rajib, Md Ismail Hossen, Md. Taufiqur Rahman Bhuiyan, Shahinur Haque, Prasanta Kumar Biswas, Amirul Islam Bhuiyan, Zahid Hasan Khan, Mohammad Ashraful Amin, Aninda Rahman, S M Shahriar Rizvi, Lucy Breakwell   +20 more
doaj   +2 more sources

Cholera Vaccines [PDF]

Journal of Travel Medicine, 2000
Cholera causes significant morbidity and mortality worldwide. For travelers, the risk of developing cholera per month of stay in a developing country is approximately 0.001%-0.01%, and cholera may present as traveler's diarrhea. In the United States, only a poorly tolerated, marginally effective, parenterally administered, phenol-inactivated vaccine is
E T, Ryan, S B, Calderwood
openaire   +4 more sources

Assessment of Stability of Chemical Cholera Vaccine in a New Primary Packaging

Проблемы особо опасных инфекций, 2023
The bivalent chemical cholera vaccine is the only drug for the prevention of cholera registered in the Russian Federation. The vaccine has been produced in glass bottles containing 210 tablets.
O. V. Gromova, S. A. Vorob’eva, O. A. Volokh, O. D. Klokova, L. F. Livanova, N. I. Belyakova, E. Z. Popova, O. A. Lobovikova, I. V. Shul’gina, I. G. Shvidenko, A. K. Nikiforov   +10 more
doaj   +1 more source

Methods to assess the impact of mass oral cholera vaccination campaigns under real field conditions. [PDF]

PLoS ONE, 2014
There is increasing interest to use oral cholera vaccination as an additional strategy to water and sanitation interventions against endemic and epidemic cholera.
Jacqueline Deen, Mohammad Ali, David Sack   +2 more
doaj   +1 more source